Want to see IXHL full AI Analyst Report?
Top Page
Incannex Healthcare Limited Sponsored ADR
(NASDAQ:IXHL)
Select Model
Select Model
Rating:49Neutral
Price Target:
$2.50
▼(-33.33% Downside)
Action:Reiterated
Date:09/26/26
The score is held down primarily by weak financial performance (ongoing losses and cash burn with minimal revenue) and limited valuation support (negative P/E, no dividend yield). Offsetting factors include a relatively strong, low-debt balance sheet and constructive corporate developments (Phase 2 trial progress and non-dilutive funding). Technical indicators are broadly neutral and do not materially change the outlook.
Positive Factors
Clinical development progress
Starting patient dosing advances IHL-42X from prior efficacy evidence toward the dose definition needed for registration studies. FDA-informed trial design and Fast Track status may improve development quality and regulatory alignment, although commercialization still depends on future results.
Negative Factors
Pre-commercial revenue weakness
The absence of meaningful current revenue leaves the company without an operating earnings base to support research and development. Persistent losses indicate that financial performance remains dependent on successful future commercialization rather than established product demand or operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical development progress
Starting patient dosing advances IHL-42X from prior efficacy evidence toward the dose definition needed for registration studies. FDA-informed trial design and Fast Track status may improve development quality and regulatory alignment, although commercialization still depends on future results.
Read all positive factors
Incannex Healthcare Limited Sponsored ADR (IXHL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.74M
Dividend YieldN/A
Average Volume (3M)84.86K
Price to Earnings (P/E)―
Beta (1Y)3.97
Revenue Growth-100.00%
EPS Growth95.90%
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding12,544,627
10 Day Avg. Volume71,741
30 Day Avg. Volume84,856
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-3.40
Enterprise Value/Market Cap-0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Incannex Healthcare Limited Sponsored ADR Business Overview & Revenue Model
Company Description
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. ...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Incannex’s ability to generate recurring operating revenue from product sales is typically limited until it has one or more therapies approved and commercialized; specific, current revenue breakdown d...
Incannex Healthcare Limited Sponsored ADR Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
63
Positive
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Sep 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 86.00K | 12.00K | 0.00 | 785.15K |
| Gross Profit | -240.00K | -160.00K | 12.00K | 0.00 | 778.79K |
| EBITDA | -22.79M | -23.54M | -27.75M | -20.39M | -5.19M |
| Net Income | -19.30M | -46.88M | -18.46M | -73.47M | -14.90M |
Balance Sheet | |||||
| Total Assets | 72.98M | 20.45M | 17.05M | 35.80M | 38.01M |
| Cash, Cash Equivalents and Short-Term Investments | 67.71M | 15.04M | 5.86M | 33.29M | 37.50M |
| Total Debt | 96.00K | 258.00K | 373.00K | 784.16K | 0.00 |
| Total Liabilities | 5.61M | 7.06M | 5.83M | 4.45M | 2.02M |
| Stockholders Equity | 67.37M | 13.39M | 11.22M | 31.34M | 36.00M |
Cash Flow | |||||
| Free Cash Flow | -12.88M | -12.52M | -16.12M | -16.65M | -12.85M |
| Operating Cash Flow | -12.87M | -12.51M | -15.85M | -16.18M | -12.85M |
| Investing Cash Flow | -94.00K | -8.00K | -277.00K | -475.61K | 0.00 |
| Financing Cash Flow | 65.90M | 21.40M | 0.00 | 12.30M | 41.18M |
Incannex Healthcare Limited Sponsored ADR Technical Analysis
Negative
3.75
Price Trends
3.25
Negative
3.29
Negative
4.38
Negative
Market Momentum
-0.18
Positive
27.72
Positive
15.00
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IXHL, the sentiment is Negative. The current price of 3.75 is above the 20-day moving average (MA) of 2.97, above the 50-day MA of 3.25, and below the 200-day MA of 4.38, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 27.72 is Positive, neither overbought nor oversold. The STOCH value of 15.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IXHL.
Incannex Healthcare Limited Sponsored ADR Risk Analysis
Incannex Healthcare Limited Sponsored ADR disclosed 68 risk factors in its most recent earnings report. Incannex Healthcare Limited Sponsored ADR reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Incannex Healthcare Limited Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $32.74M | -2.33 | -18.27% | ― | -100.00% | 95.90% | |
46 Neutral | $37.68M | -3.68 | -45.89% | 0.37% | -100.00% | 68.62% | |
46 Neutral | $34.71M | -3.30 | -91.11% | ― | ― | 35.47% | |
43 Neutral | $6.95M | -0.15 | -329.08% | ― | ― | -19.07% | |
42 Neutral | $8.88M | -0.19 | 3398.40% | ― | ― | 15.37% |
* Healthcare Sector Average
IXHL
Incannex Healthcare Limited Sponsored ADR
2.62
-8.12
-75.60%
VERU
Veru
2.28
-1.37
-37.53%
NNVC
NanoViricides
1.46
-0.07
-4.58%
LEXX
Lexaria Bioscience
3.22
-11.07
-77.46%
SKYE
Skye Bioscience
1.45
-11.03
-88.38%
CALC
CalciMedica
1.31
-14.24
-91.58%
Incannex Healthcare Limited Sponsored ADR Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related AnnouncementsRegulatory Filings and Compliance
Incannex Begins Phase 2 DReAMzz Sleep Apnea Study
Positive
Sep 9, 2026
On September 9, 2026, Incannex Healthcare reported that patient dosing has begun in DReAMzz, a Phase 2 crossover dose-optimization study of IHL-42X for obstructive sleep apnea at 13 sites in the U.S., building on positive Phase 2 RePOSA data from ...
Business Operations and StrategyProduct-Related Announcements
Incannex Begins Phase 2 DReAMzz Trial for IHL-42X
Positive
Aug 25, 2026
On August 25, 2026, Incannex Healthcare announced that the first patient has been dosed in its DReAMzz Phase 2 dose-optimization study of IHL-42X, a proprietary oral fixed-dose combination of dronabinol and acetazolamide for obstructive sleep apne...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Incannex Secures A$5.1M R&D Tax Incentive Refund
Positive
Aug 11, 2026
On August 11, 2026, Incannex Healthcare announced it had received a final A$5.1 million refund under the Australian Government’s Research and Development Tax Incentive Program after amending its FY25 income tax return to reflect approved ove...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.